Stockscreener 앱 받기
21.35
0.74%
-0.16
시간 외 거래:
21.35
전일 마감가:
$21.51
열려 있는:
$21.5
하루 거래량:
1.05M
Relative Volume:
1.40
시가총액:
$1.58B
수익:
$425.13M
순이익/손실:
$271.17M
주가수익비율:
6.9879
EPS:
3.0553
순현금흐름:
$195.80M
1주 성능:
-5.86%
1개월 성능:
-7.62%
6개월 성능:
+1.76%
1년 성능:
+6.01%
1일 변동 폭
$21.28
$21.71
1주일 범위
$21.24
$22.90
52주 변동 폭
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
명칭
Innoviva Inc
전화
(650) 238-9600
주소
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
21.35 | 1.59B | 425.13M | 271.17M | 195.80M | 3.0553 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 개시 | BTIG Research | Buy |
| 2025-09-30 | 개시 | Goldman | Sell |
| 2025-08-11 | 개시 | Oppenheimer | Outperform |
| 2025-07-14 | 개시 | H.C. Wainwright | Buy |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-20 | 개시 | Goldman | Neutral |
| 2017-11-20 | 개시 | Deutsche Bank | Hold |
모두보기
Innoviva Inc 주식(INVA)의 최신 뉴스
Innoviva to Participate in Upcoming Investor Conferences - Business Wire
INVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $46 - GuruFocus
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More - AOL.com
Has Innoviva Successfully Pivoted Beyond its Royalty Roots - Kavout
INVA Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineFull Year Guidance - thelegaladvocate.com
INVA Q1 2026 Earnings: EPS Miss Triggers 2% Stock DeclineDividend Cut Risk - thelegaladvocate.com
Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI), NeOnc Technologies Holdings, Inc. (NTHI) and Innoviva (INVA) - The Globe and Mail
INVA Reiterates by BTIG -- Price Target Maintained at $42 - GuruFocus
Innoviva Inc. (INVA) Gains Ground Amid Sector DynamicsPost-Earnings Moves - thelegaladvocate.com
INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals - ChartMill
The Technical Signals Behind (INVA) That Institutions Follow - Stock Traders Daily
INVA Q1 2026 Earnings: Significant EPS Miss Amid Lack of Revenue DisclosureOne-Time Loss Impact - Newser
INVA Q1 2026 Earnings: EPS Misses Estimates Despite Modest Stock GainOpen Signal Network - Newser
Innoviva (INVA) CFO adds ESPP shares and uses stock to pay taxes - Stock Titan
Innoviva (INVA) CEO logs ESPP share grant and tax withholding on Form 4 - Stock Titan
Innoviva (NASDAQ: INVA) CAO has shares withheld to cover tax obligations - Stock Titan
Innoviva (INVA) Q1 2026 Earnings Miss by Significant: Key TakeawaysHot Momentum Watchlist - Newser
Innoviva Appoints Josephine Linden to Strengthen Board Oversight - TipRanks
Innoviva Board Shakeup Puts Governance And Valuation In Focus - Sahm
Innoviva (INVA) director receives RSU and stock option grants as board compensation - Stock Titan
Innoviva (INVA) director Josephine Linden files Form 3 showing no share ownership - Stock Titan
Innoviva announces board changes and appoints Josephine Linden as director - Investing.com Nigeria
Innoviva (INVA) refreshes board as two directors resign, adds Josephine Linden - Stock Titan
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Sahm
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Precision Trading with Innoviva Inc. (INVA) Risk Zones - Stock Traders Daily
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Quantisnow
TradingKey - TradingKey
Why are smart money investors paying attention to Innoviva (INVA)? (Mini Rally) 2026-05-11Professional Trade Ideas - newser.com
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness? - Yahoo Finance
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders - simplywall.st
Innoviva Inc Emerges as Top Small Cap Value Stock with High Royalty Revenues - HarianBasis.co
Innoviva (INVA) Q1 Profit Swing Challenges Bearish Earnings Decline Narratives - Sahm
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength - Insider Monkey
INVA SEC FilingsInnoviva 10-K, 10-Q, 8-K Forms - Stock Titan
BTIG Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Goldman Sachs Maintains Innoviva(INVA.US) With Sell Rating, Raises Target Price to $18 - Moomoo
MSN Money - MSN
Innoviva: Q1 Earnings Snapshot - theheraldreview.com
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress - BioSpace
Innoviva (INVA) Tops Q1 Earnings Estimates - Yahoo Finance
Innoviva Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Innoviva Inc (INVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.89%
자본화:
|
볼륨(24시간):